Successfully translating anti-cancer nanomedicines from pre-clinical proof of concept to
demonstration of therapeutic value in the clinic is challenging. Having made significant …

Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a promising therapeutic
approach that aims to stabilize the progression of solid malignancies by abrogating tumor-…

Oncogenic KRAS mutations and inactivation of the APC tumor suppressor co-occur in
colorectal cancer (CRC). Despite efforts to target mutant KRAS directly, most therapeutic …

Efforts to apply nanotechnology in cancer have focused almost exclusively on the delivery
of cytotoxic drugs to improve therapeutic index. There has been little consideration of …

Enhanced permeability of the tumor vasculature allows macromolecules to enter the tumor
interstitial space, whereas the suppressed lymphatic filtration allows them to stay there. This …

CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive
properties. Here we show that CXCR2 signaling is upregulated in human pancreatic cancer, …

Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational
profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils — termed ‘…

The metastatic process of colorectal cancer (CRC) is not fully understood and effective
therapies are lacking. We show that activation of NOTCH1 signaling in the murine intestinal …

Cholangiocarcinoma (CC) is typically diagnosed at an advanced stage and is refractory to
surgical intervention and chemotherapy. Despite a global increase in the incidence of CC, …